These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22707102)

  • 1. Rifampin breakpoint for Acinetobacter baumannii based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation.
    Lepe JA; García-Cabrera E; Gil-Navarro MV; Aznar J
    Rev Esp Quimioter; 2012 Jun; 25(2):134-8. PubMed ID: 22707102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
    Zazo H; Martín-Suárez A; Lanao JM
    Int J Antimicrob Agents; 2013 Aug; 42(2):155-60. PubMed ID: 23756322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections.
    Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Morikawa N; Takeda Y
    J Infect Chemother; 2015 Apr; 21(4):284-9. PubMed ID: 25638291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia.
    Bernabeu-Wittel M; Pichardo C; García-Curiel A; Pachón-Ibáñez ME; Ibáñez-Martínez J; Jiménez-Mejías ME; Pachón J
    Clin Microbiol Infect; 2005 Apr; 11(4):319-25. PubMed ID: 15760430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations.
    Khachman D; Conil JM; Georges B; Saivin S; Houin G; Toutain PL; Laffont CM
    J Antimicrob Chemother; 2011 Aug; 66(8):1798-809. PubMed ID: 21653603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii.
    Ni WT; Liang BB; Cai Y; Liu YP; Bai N; Cui JC; Wang R
    Pak J Pharm Sci; 2014 May; 27(3):463-7. PubMed ID: 24811802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for the treatment of polymyxin B-resistant Acinetobacter baumannii infections.
    Menegucci TC; Albiero J; Migliorini LB; Alves JL; Viana GF; Mazucheli J; Carrara-Marroni FE; Cardoso CL; Tognim MC
    Int J Antimicrob Agents; 2016 May; 47(5):380-5. PubMed ID: 27068675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009.
    Morfin-Otero R; Dowzicky MJ
    Clin Ther; 2012 Jan; 34(1):101-12. PubMed ID: 22177546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of colistin and ampicillin/sulbactam against Acinetobacter baumannii.
    Punpanich W; Munsrichoom A; Srisarang S; Treeratweeraphong V
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S95-100. PubMed ID: 22043760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
    Dong J; Xiong W; Chen Y; Zhao Y; Lu Y; Zhao D; Li W; Liu Y; Chen X
    Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment.
    DeRyke CA; Kuti JL; Nicolau DP
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):337-44. PubMed ID: 17350206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole.
    Sprandel KA; Drusano GL; Hecht DW; Rotschafer JC; Danziger LH; Rodvold KA
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):303-9. PubMed ID: 16887471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan.
    Liu JW; Wang LS; Cheng YJ; Hsu GJ; Lu PL; Liu YC; Chen CM; Lee CM; Sun W; Jang TN; Chiang PC; Chuang YC; Lin HC; Shi ZY; Kung HC; Huang CH; Tsao SM; Lu CT; Liao CH; Hsueh PR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S188-91. PubMed ID: 19013353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semi-mechanistic PK/PD modelling of meropenem and sulbactam combination against carbapenem-resistant strains of Acinetobacter baumannii.
    Mohd Sazlly Lim S; Heffernan AJ; Zowawi HM; Roberts JA; Sime FB
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1943-1952. PubMed ID: 33884516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis.
    Burgess DS; Frei CR; Lewis Ii JS; Fiebelkorn KR; Jorgensen JH
    Clin Microbiol Infect; 2007 Jan; 13(1):33-9. PubMed ID: 17184285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.